Le Lézard
Classified in: Science and technology
Subjects: Conference, Product/Service, Trade Show

NantHealth® Showcases DeviceConXtm Version 5.15 at Vitalis, Largest eHealth Event in Scandinavia

NantHealth, Inc. (NASDAQ: NH), a leader in connected care solutions, showcases DeviceConXtm Version 5.15 at Vitalis, one of the largest e-health events in Scandinavia. NantHealth's Connected Care solutions integrate medical device data into clinical records which may lead to reduced length of stay, less costly medical errors, greater provider satisfaction and improved outcomes.

An extremely flexible software-based platform designed for complete connectivity and interoperability, DeviceConX facilitates the capture of patient data from any capable medical device. Leveraging a combination of existing hardware investments?including bedside PCs, laptops, tablets, workstations-on-wheels, and NantHealth's HBox hardware?DeviceConX can then deliver that medical device data to an EMR or any other clinical system quickly and accurately.

The latest DeviceConX version 5.15 includes the ability to:

"The need for interoperability in health care technology has reached an all-time high. We see it at the health IT conferences we attend and in the ongoing dialogue we have with our customers," explains Wes Madden, BSN, RN, Vice President of Connected Care, NantHealth. "We are excited about the innovative enhancements we've made to DeviceConX version 5.15 and look forward to having our European customers experience a more streamlined workflow while reducing costly medical errors."

About NantHealth

NantHealth, a member of the NantWorks ecosystem of companies, provides leading solutions across the continuum of care for physicians, payers, patients and biopharmaceutical organizations. NantHealth enables the use of cutting-edge data and technology towards the goal of empowering clinical decision support and improving patient outcomes. NantHealth's comprehensive product portfolio combines the latest technology in molecular analysis (GPS Cancer® and Liquid GPS®), payer/provider platforms that exchange information in near-real time (NaviNet and Eviti), and connected care solutions that deliver Medical Device Interoperability (MDI). NantHealth's GPS Cancer® molecular profiling provides comprehensive DNA & RNA tumor-normal profiling combined with pharmacogenomics analysis. Liquid GPS® provides non-invasive testing of cfDNA and cfRNA to monitor cancer mutations and potentially select targeted therapies, chemotherapies, and immunotherapies. For more information, please visit www.nanthealth.com and follow us on Twitter, Facebook and LinkedIn.

These press releases may also interest you

at 16:05
VBI Vaccines Inc. (VBI or the Company), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that it has commenced an underwritten public offering of its common...

at 16:04
Baylin Technologies Inc. (the "Company" or "Baylin"). At the Company's annual general meeting of shareholders held on May 15, 2019, Mr. David Gelerman, who was standing for election as a director, received 8,077,196...

at 16:03
Baylin Technologies Inc. (the "Company" or "Baylin"). Challenging industry dynamics have continued to soften demand from several of Baylin's primary customers. As a result, third quarter financial metrics are expected...

at 16:03
Etsy, Inc. , which operates two-sided online marketplaces that connect millions of passionate and creative buyers and sellers around the world, today announced that it intends to offer, subject to market conditions and other factors, $650.0 million...

at 16:02
Baylin Technologies is pleased to announce that its wholly owned subsidiary, Galtronics Vietnam Co. Ltd. ("Galtronics"), has been selected as one of a few vendors to supply a tier one network equipment provider with 3.5GHz 5G MMU (Massive MIMO Unit)...

at 16:01
China Biologic Products Holdings, Inc. , a leading fully integrated plasma-based biopharmaceutical company in China, today announced that its board of directors (the "Board") has received a preliminary non-binding proposal letter, dated September 18,...

News published on 21 may 2019 at 11:20 and distributed by: